Press Releases

Date	Title	PDF Version
Jun 19, 2018	Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.
Jun 14, 2018	Alexion Announces Selection of Positive Phase 3 Clinical Data for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for Late-Breaking Oral Presentation at Annual Conference of the European Hematology Association (EHA)
Jun 11, 2018	Alexion and Complement Pharma Announce Partnership to Co-Develop Pre-Clinical Complement Inhibitor for Neurodegenerative Disorders
Jun 05, 2018	Alexion to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
May 25, 2018	Alexion Offer for Wilson Therapeutics Accepted
May 08, 2018	Alexion to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
Apr 26, 2018	Alexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study
Apr 12, 2018	Alexion to Report First Quarter 2018 Results on Thursday, April 26, 2018
Apr 11, 2018	Alexion to Acquire Wilson Therapeutics
Mar 15, 2018	Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Search